Incidence of diabetic macular edema and the need for glaucoma surgery were reduced after treatment with glucagon-like peptide-1 receptor agonists.
|Articles|June 10, 2012
VIDEO: Roman Hovorka, PhD, Talks About the Cost and Coverage Issues Associated with Continuous Glucose Monitoring
Roman Hovorka, PhD, talks about the prohibitive costs in continuous glucose monitoring. He states that if these costs can be reduced there will be wider acceptance and therefore a benefit to diabetes care.
Advertisement
Roman Hovorka, PhD, talks about the prohibitive costs in continuous glucose monitoring. He states that if these costs can be reduced there will be wider acceptance and therefore a benefit to diabetes care.
According to Hovorka, there are more issues in the United Kingdom compared to the United States at this time, although the costs of of continuous glucose monitoring prohibit widespread use in both countries.
Advertisement
Related to this article
Two inSPire2026 posters detail how health system specialty pharmacy teams support patients with ATTR-CM.
The conference, held in New Orleans, Louisiana, by the American Academy of Ophthalmology, will offer 3 full days of content spanning from glaucoma to dry eye.
Stutsky explains why shifting therapy perceptions had more pharmacist touchpoints and longer time on therapy among patients with ATTR-CM.
Panelists ask whether cancer care will shift toward home-administered infusions as payers push for change. Other topics in this forward-looking session include new delivery tech and practice-led solutions.
Advertisement
Advertisement
Trending on AJMC
1
MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MD
2
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
3
5 Things to Know About Eye Injury Prevention Month
4
Multi-Hit TP53 Linked to Shorter Survival in Chronic-Phase MPN Cohorts
5